Mechanisms of big endothelin-1-induced diuresis and natriuresis : role of ET(B) receptors

Hypertension. 2000 Mar;35(3):732-9. doi: 10.1161/01.hyp.35.3.732.

Abstract

Endothelin-1 (ET-1) at high concentrations has marked antidiuretic and antinatriuretic activities, whereas its precursor, big endothelin-1 (big ET-1), has surprisingly potent diuretic and natriuretic actions. The mechanisms underlying the excretory effects of big ET-1 have not been fully elucidated. To explore these mechanisms, we examined the effects of a highly selective ET(B) antagonist (A-192621.1), a calcium channel blocker (verapamil), a nitric oxide synthase inhibitor (N-nitro-L-arginine methyl ester [L-NAME]), and a cyclooxygenase inhibitor (indomethacin) on the systemic and renal actions of big ET-1 in anesthetized rats. An intravenous bolus injection of incremental doses of big ET-1 (0.3, 1. 0, and 3.0 nmol/kg) produced a significant hypertensive effect that was dose dependent and prolonged (from 113+/-7 mm Hg to a maximum of 148+/-6 mm Hg). The administration of big ET-1 induced marked diuretic and natriuretic responses (urinary flow rate increased from 8.5+/-1 to 110+/-14 microL/min, and fractional excretion of sodium increased from 0.38+/-0.13% to 7.51+/-1.24%). Glomerular filtration rate and renal plasma flow significantly decreased only at the highest dose of big ET-1. Pretreatment with A-192621.1 (3 mg/kg plus 3 mg. kg(-1). h(-1)) significantly abolished the diuretic (17+/-5 microL/min to a maximum of 19+/-3 microL/min) and natriuretic (0. 29+/-0.1% to a maximum of 1.93+/-0.37%) responses induced by big ET-1. Moreover, A-192621.1 potentiated the decline in glomerular filtration rate and renal plasma flow and the increase in mean arterial blood pressure produced by the low doses of big ET-1. Similar to A-192621.1, pretreatment with a nitric oxide synthase inhibitor (L-NAME, 10 mg/kg plus 5 mg. kg(-1). h(-1)) significantly and comparably reduced the diuretic and natriuretic actions of big ET-1 and augmented the hypoperfusion/hypofiltration and systemic vasoconstriction induced by high doses of the peptide. Pretreatment with verapamil (2 mg. kg(-1). h(-1)) slightly inhibited the diuretic/natriuretic effects of the high-dose big ET-1 and completely prevented the increase in mean arterial blood pressure provoked by the peptide. Unlike verapamil and L-NAME, only indomethacin administration was associated with significant natriuretic/diuretic responses and did not influence the pressor effect and renal actions of big ET-1. Taken together, these results suggest that big ET-1-induced diuretic and natriuretic responses are mediated mainly by stimulation of nitric oxide production coupled to ET(B) receptor subtype activation.

MeSH terms

  • Animals
  • Calcium / metabolism
  • Calcium Channel Blockers / pharmacology
  • Cardiovascular Agents / pharmacology
  • Cytosol / metabolism
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Endothelins / pharmacology*
  • Enzyme Inhibitors / pharmacology
  • Glomerular Filtration Rate / drug effects
  • Glomerular Filtration Rate / physiology
  • Indomethacin / pharmacology
  • Kidney / chemistry
  • Kidney / drug effects
  • Kidney / physiology
  • Male
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Natriuresis / drug effects*
  • Natriuresis / physiology*
  • Nitric Oxide / metabolism
  • Prostaglandins / metabolism
  • Protein Precursors / pharmacology*
  • Pyrrolidines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Endothelin B
  • Receptors, Endothelin / physiology*
  • Urination / drug effects
  • Urination / physiology
  • Verapamil / pharmacology

Substances

  • A 192621
  • Calcium Channel Blockers
  • Cardiovascular Agents
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Endothelins
  • Enzyme Inhibitors
  • Prostaglandins
  • Protein Precursors
  • Pyrrolidines
  • Receptor, Endothelin B
  • Receptors, Endothelin
  • Nitric Oxide
  • Verapamil
  • Calcium
  • NG-Nitroarginine Methyl Ester
  • Indomethacin